Once-monthly Invega approved for schizophrenia in the US
This article was originally published in Scrip
Executive Summary
The US FDA has approved Johnson & Johnson's once-monthly injectable version of its oral antipsychotic Invega (paliperidone palmitate), branded Invega Sustenna, for the acute and maintenance treatment of schizophrenia in adults.